Novartis Q1 2026 Results: Strong Growth in Priority Brands Amid Generic Erosion
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Tag: Novartis
Novartis Immunology Data at AAD 2026: Rhapsido and Cosentyx Results
Novartis unveils over 20 abstracts at AAD 2026, highlighting Rhapsido’s (remibrutinib) early intervention in CSU and Cosentyx’s (secukinumab) sustained performance in complex skin diseases.
Novartis Declares Cosentyx FDA Approval for Pediatric Patients: The First IL-17A Inhibitor to Transform Hidradenitis Suppurativa Treatment
osentyx FDA approval marks first IL-17A inhibitor for pediatric patients 12+ with hidradenitis suppurativa. Discover how this breakthrough treatment transforms care for adolescents facing HS.
Novartis Completes $12 Billion Acquisition of Avidity Biosciences, Strengthening RNA Neuroscience Pipeline
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has officially closed its acquisition of San Diego-based Avidity Biosciences, marking one of the most significant deals in the neuromuscular disease space in recent years. The transaction, originally announced on October 26, 2025, values Avidity at approximately $12 billion on a fully diluted basis, with an enterprise value of roughly $11 billion.
Novartis Achieves Phase III Remibrutinib Trial Primary Endpoint in Chronic Inducible Urticaria
Novartis announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU), demonstrating the potential to become [Read More…]
Novartis Vanrafia® Phase III Data Show Significant Slowing of Kidney Function Decline in IgA Nephropathy Patients
Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.
Novartis Ianalumab Clinches FDA Breakthrough Status, Aiming to Be First Targeted Treatment for Sjögren’s Disease
Novartis reaches a historic milestone in immunology as the FDA grants Breakthrough Therapy designation to ianalumab for Sjögren’s disease. Backed by successful Phase III NEPTUNUS trials, this dual-action monoclonal antibody is poised to become the first targeted therapy for this chronic autoimmune condition. With global regulatory submissions planned for early 2026, ianalumab represents a significant leap forward for millions of patients currently facing an immense unmet medical need.
Novartis Receives FDA Approval for Itvisma, Expanding Gene Therapy to Older Children and Adults with SMA
Novartis has secured FDA approval for Itvisma (onasemnogene abeparvovec-brve), marking a historic milestone as the first gene replacement therapy for spinal muscular atrophy (SMA) available to children aged two and older, teens, and adults. This one-time intrathecal injection offers a “game-changing” new treatment option for patients previously ineligible for gene therapy.
